Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study.

Autor:	Thompson P; Division of Infectious Diseases, Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA. Electronic address: peyton_thompson@med.unc.edu., Morgan CE; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA., Ngimbi P; Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo., Mwandagalirwa K; Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo., Ravelomanana NLR; Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo., Tabala M; Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo., Fathy M; Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo., Kawende B; Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo., Muwonga J; National AIDS Control Program, Kinshasa, Democratic Republic of the Congo., Misingi P; National Blood Transfusion Program, Kinshasa, Democratic Republic of the Congo., Mbendi C; Department of Gastroenterology, University Hospital, Kinshasa, Democratic Republic of the Congo., Luhata C; Expanded Programme on Immunisation, Kinshasa, Democratic Republic of the Congo., Jhaveri R; Department of Pediatrics, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Cloherty G; Abbott Laboratories, Abbott Park, IL, USA., Kaba D; Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo., Yotebieng M; Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, New York City, NY, USA., Parr JB; Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Jazyk:	angličtina
Zdroj:	The Lancet. Global health [Lancet Glob Health] 2021 Nov; Vol. 9 (11), pp. e1600-e1609. Date of Electronic Publication: 2021 Aug 17.
DOI:	10.1016/S2214-109X(21)00304-1
Abstrakt:	Background: Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective childhood vaccines. In the Democratic Republic of the Congo, HBV treatment and birth-dose vaccination programmes are not established. We, therefore, aimed to evaluate the feasibility and acceptability of adding HBV testing and treatment of pregnant women as well as the birth-dose vaccination of HBV-exposed infants to the HIV prevention of mother-to-child transmission programme infrastructure in the Democratic Republic of the Congo. Methods: We did a feasibility study in two maternity centres in Kinshasa: Binza and Kingasani. Using the already established HIV prevention of mother-to-child transmission programme at these two maternity centres, we screened pregnant women for HBV infection at routine prenatal care registration. Those who tested positive and had a gestational age of 24 weeks or less were included in this study. Eligible pregnant women with a high viral load (≥200 000 IU/mL or HBeAg positivity, or both) were considered as having HBV of high risk of mother-to-child transmission and initiated on oral tenofovir disoproxil fumarate (300 mg/day) between 28 weeks and 32 weeks of gestation and continued through 12 weeks post partum. All HBV-exposed infants received a birth-dose of monovalent HBV vaccine (Euvax-B Pediatric: Sanofi Pasteur, Seoul, South Korea; 0·5 mL) within 24 h of life. All women were followed up for 24 weeks post partum, when they completed an exit questionnaire that assessed the acceptability of study procedures. The primary outcomes were the feasibility of screening pregnant women to identify those at high risk for HBV mother-to-child transmission and to provide them with antiviral prophylaxis, the feasibility of administrating the birth-dose vaccine to exposed infants, and the acceptability of this prevention programme. This study is registered with ClinicalTrials.gov, NCT03567382. Findings: Between Sept 24, 2018, and Feb 22, 2019, 4016 women were approached and screened. Of these pregnant women, 109 (2·7%) were positive for HBsAg. Of the 109 women, 91 (83%) met the eligibility criteria for participation. However, only data from 90 women-excluding one woman who had a false pregnancy-were included in the study analysis. The median overall age of the enrolled women was 31 years (IQR 25-34) and the median overall gestational age was 19 weeks (15-22). Ten (11%) of 91 women evaluated had high-risk HBV infection. Nine (90%) of the ten pregnant women with high-risk HBV infection received tenofovir disoproxil fumarate and one (10%) refused therapy and withdrew from the study; five (56%) of the nine women achieved viral suppression (ie, <200 000 IU/mL) on tenofovir disoproxil fumarate therapy by the time of delivery and the remaining four (44%) had decreased viral loads from enrolment to delivery. A total of 88 infants were born to the 90 enrolled women. Of the 88 infants, 60 (68%) received a birth-dose vaccine; of these, 46 (77%) received a timely birth-dose vaccine. No cases of HBV mother-to-child transmission were observed. No serious adverse events associated with tenofovir disoproxil fumarate nor with the birth-dose vaccine were reported. Only one (11%) of nine women reported dizziness during the course of tenofovir disoproxil fumarate therapy. The study procedures were considered highly acceptable (>80%) among mothers. Interpretation: Adding HBV screening and treatment of pregnant women and infant birth-dose vaccination to existing HIV prevention of mother-to-child transmission platforms is feasible in countries such as the Democratic Republic of the Congo. Birth-dose vaccination against HBV infection integrated within the current Expanded Programme on Immunisation and HIV prevention of mother-to-child transmission programme could accelerate progress toward HBV elimination in Africa. Funding: Gillings Innovation Laboratory award and the National Institutes of Health. Translations: For the French and Lingala translations of the abstract see Supplementary Materials section. Competing Interests: Declaration of interests PT and JBP report support from the American Society of Tropical Medicine and Hygiene–Burroughs Wellcome Fund awards, outside the submitted work. PT, RJ, and JBP report research support from Gilead Sciences, outside the submitted work. JBP reports grants from the US National Institutes of Health (NIH), outside the submitted work. CEM reports a grant from the Infectious Diseases Society of America, outside the submitted work. RJ reports consulting fees from Dynavax, outside the submitted work; membership on the American Association for the Study of Liver Diseases (AASLD)–Infections Diseases Society of America Hepatitis C Virus Guidelines panel and the AASLD Viral Hepatitis Elimination Task Force; and a stipend from Elsevier for editorial services as Co-Editor-in-Chief of Clinical Therapeutics. GC is an employee and shareholder of Abbott Laboratories. JBP reports research support from WHO and honoraria from Virology Education, outside the submitted work. All other authors declare no competing interests. (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu